Special Issue

Biomarkers, Surrogate Markers and New Therapeutic Insights into Multiple Sclerosis

Message from the Guest Editor

Multiple sclerosis (MS) remains a demyelinating disease of the central nervous system with an unknown etiology. Several disease-modifying treatments (DMTs) are now available, including immunomodulating agents, immunosuppressant agents, and sequestrant drugs. Research into other molecules, such as Bruton tyrosine kinase inhibitors, is ongoing. Despite this therapeutic armamentarium, which can prevent neuroinflammation, lesion loads, and clinical relapses, silent clinical progression can still occur based on smoldering lesions. This phenomenon results in slow clinical worsening independent of relapses, suggesting a biological continuum of MS's pathology, progressing from the onset to the end-stage of the disease. This continuum makes clinical phenotypes the epiphenomenon of the disease phase, while biomarkers fail to meet the real needs of monitoring disease activity and the response to therapy. Although the Neurofilament light chain, CD20, and Retinal Nerve Fiber Layer already represent emerging tools in this field, the study of earlier and more specific indicators is still warranted in MS.

Guest Editor

Dr. Roberto De Masi

Complex Operative Unit of Neurology, "F. Ferrari" Hospital, Casarano, 73042 Lecce, Italy

Deadline for manuscript submissions

closed (30 June 2025)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/227401

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).